Literature DB >> 26965175

Acute liver failure due to primary amyloidosis in a nephrotic syndrome: a swiftly progressive course.

Brigite Aguiar Cardoso1, Rita Leal2, Helena Sá2, Mário Campos2.   

Abstract

AL amyloidosis is a clonal plasma cell proliferative disorder characterised by extracellular tissue deposits of insoluble fibrils derived from κ or λ immunoglobulin light chains. The most common organs affected by AL amyloidosis are the kidney, presenting with nephrotic syndrome and/or progressive renal dysfunction, and the heart, with restrictive cardiomyopathy. Hepatic deposition of fibrils occurs in half the cases but the liver is rarely the predominantly affected organ. The most common presentation of hepatic amyloidosis is hepatomegaly with elevated alkaline phosphatase. Acute liver failure with cholestasis and jaundice is a rare complication, with a prevalence of approximately 5%, and is usually associated with a worse prognosis. We report a case of a 39-year-old man admitted to our nephrology department with an unusual presentation of primary amyloidosis with nephrotic syndrome and acute liver failure, complicated by obstructive cholestasis resulting in death 2 months after diagnosis. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 26965175      PMCID: PMC4785491          DOI: 10.1136/bcr-2016-214392

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  22 in total

Review 1.  Systemic amyloidosis: a challenge for the rheumatologist.

Authors:  Federico Perfetto; Alberto Moggi-Pignone; Riccardo Livi; Alessio Tempestini; Franco Bergesio; Marco Matucci-Cerinic
Journal:  Nat Rev Rheumatol       Date:  2010-06-08       Impact factor: 20.543

2.  Subacute liver failure secondary to amyloid light-chain amyloidosis.

Authors:  Theresa J Hydes; Richard J Aspinall
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-03

3.  [Subacute renal failure as a form of presentation of Al-amyloidosis].

Authors:  C Vozmediano; A Carreño; J Blanco; F Rivera
Journal:  Nefrologia       Date:  2007       Impact factor: 2.033

4.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

Review 5.  Treatment of immunoglobulin light chain amyloidosis.

Authors:  Morie A Gertz; Steven R Zeldenrust
Journal:  Curr Hematol Malig Rep       Date:  2009-04       Impact factor: 3.952

Review 6.  Primary systemic amyloidosis--a diagnostic primer.

Authors:  M A Gertz; R A Kyle
Journal:  Mayo Clin Proc       Date:  1989-12       Impact factor: 7.616

Review 7.  Amyloid and the GI tract.

Authors:  Prayman Sattianayagam; Philip Hawkins; Julian Gillmore
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2009-12       Impact factor: 3.869

8.  Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients.

Authors:  Miguel A Park; Paul S Mueller; Robert A Kyle; Dirk R Larson; Matthew F Plevak; Morie A Gertz
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

Review 9.  Amyloidosis (AL). Clinical and laboratory features in 229 cases.

Authors:  R A Kyle; P R Greipp
Journal:  Mayo Clin Proc       Date:  1983-10       Impact factor: 7.616

10.  Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients.

Authors:  M A Gertz; R A Kyle
Journal:  Am J Med       Date:  1988-07       Impact factor: 4.965

View more
  1 in total

1.  A comprehensive validation of HBV-related acute-on-chronic liver failure models to assist decision-making in targeted therapeutics.

Authors:  Yi Shen; Xulin Wang; Sheng Zhang; Gang Qin; Yanmei Liu; Yihua Lu; Feng Liang; Xun Zhuang
Journal:  Sci Rep       Date:  2016-09-16       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.